

# SCIENTIFIC REPORTS

OPEN

## Hypoallergenic and anti-inflammatory feeds in children with complicated severe acute malnutrition: an open randomised controlled 3-arm intervention trial in Malawi

Rosalie H. Bartels<sup>1,2</sup>, Emmanuel Chimwezi<sup>2,3</sup>, Victoria Watson<sup>4</sup>, Leilei Pei<sup>4</sup>, Isabel Potani<sup>2</sup>, Benjamin Allubha<sup>2</sup>, Kate Chidzalo<sup>2,3</sup>, Duolao Wang<sup>4</sup>, Queen Dube<sup>5</sup>, Macpherson Mallewa<sup>5</sup>, Angela Allen<sup>6</sup>, Robert H. J. Bandsma<sup>3,7,8,9</sup>, Wieger P. Voskuil<sup>1,2,3</sup> & Stephen J. Allen<sup>4</sup>

Intestinal pathology in children with complicated severe acute malnutrition (SAM) persists despite standard management. Given the similarity with intestinal pathology in non-IgE mediated gastrointestinal food allergy and Crohn's disease, we tested whether therapeutic feeds effective in treating these conditions may benefit children with complicated SAM. After initial clinical stabilisation, 95 children aged 6–23 months admitted at Queen Elizabeth Central Hospital, Blantyre, Malawi between January 1<sup>st</sup> and December 31<sup>st</sup>, 2016 were allocated randomly to either standard feeds, an elemental feed or a polymeric feed for 14 days. Change in faecal calprotectin as a marker of intestinal inflammation and the primary outcome was similar in each arm: elemental vs. standard 4.1 µg/mg stool/day (95% CI, −29.9, 38.15;  $P = 0.81$ ) and polymeric vs. standard 10 (−23.96, 43.91;  $P = 0.56$ ). Biomarkers of intestinal and systemic inflammation and mucosal integrity were highly abnormal in most children at baseline and abnormal values persisted in all three arms. The enteropathy in complicated SAM did not respond to either standard feeds or alternative therapeutic feeds administered for up to 14 days. A better understanding of the pathogenesis of the gut pathology in complicated SAM is an urgent priority to inform the development of improved therapeutic interventions.

In 2016, severe wasting (weight-for-height Z score (WHZ)  $< -3$ ) occurred in 17 million under-fives (2.5% of all children) and was estimated to account for between 7.4–7.8% of all child deaths<sup>1–3</sup>. A small percentage of children with severe acute malnutrition (SAM) require in-patient care because of poor feeding, medical complications such as severe oedema and infection, or failure to improve under community management<sup>4</sup>. Despite following a well-established World Health Organization (WHO) protocol<sup>4</sup>, case fatality in complicated SAM remains up to 35%<sup>5–9</sup> with additional deaths after hospital discharge<sup>8,10</sup>.

Intestinal pathology in SAM is thought to result from increased exposure to microbial pathogens and poor nutrition<sup>11–15</sup>. Small intestinal biopsy studies in SAM revealed Th-1 dominated intestinal inflammation with

<sup>1</sup>Global Child Health Group, Emma Children's Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. <sup>2</sup>Department of Paediatrics and Child Health, Queen Elizabeth Central Hospital, Blantyre, Malawi. <sup>3</sup>The Childhood Acute Illness & Nutrition Network, Nairobi, Kenya. <sup>4</sup>Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK. <sup>5</sup>College of Medicine, University of Malawi, Blantyre, Malawi. <sup>6</sup>Centre for Tropical Infectious Diseases, Liverpool School of Tropical Medicine, Liverpool, UK. <sup>7</sup>Division of Gastroenterology, Hepatology and Nutrition. The Hospital for Sick Children, Toronto, Ontario, Canada. <sup>8</sup>Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. <sup>9</sup>Centre for Global Child Health, Hospital for Sick Children, Peter Gilgan Centre for Research & Learning, Toronto, Ontario, Canada. Correspondence and requests for materials should be addressed to R.H.B. (email: [rhbartels@hotmail.com](mailto:rhbartels@hotmail.com))

variable degrees of villous atrophy, crypt hyperplasia and increased inflammatory infiltrate<sup>11,16–21</sup>. A recent biopsy and biomarker study in Zambian children with SAM and persistent diarrhoea not responding to standard therapy reported severe enteropathy with intestinal barrier failure and immune dysregulation<sup>14</sup>. These histological and immune features are similar to those that occur in children with Crohn's disease<sup>22</sup> and also non-IgE-mediated gastrointestinal food allergies (hereafter “food allergy”; e.g. due to cow's milk protein) although the pathology of these latter disorders is poorly understood<sup>20,21</sup>. The similarities in the intestinal pathology in these conditions raises the intriguing possibility that treatments that reduce gut inflammation in Crohn's disease and food allergy may also be of benefit in SAM and formed the rationale for evaluating the alternative therapeutic feeds in this study.

Intestinal inflammation in food allergy responds well to exclusion of the offending dietary antigen or, if the offending antigen is not known, a hypoallergenic, elemental feed composed of single amino acids<sup>23</sup>. In paediatric Crohn's disease, first-line therapy is with exclusive enteral nutrition where all foods are replaced by an elemental formula or polymeric formula<sup>22–25</sup>. In limited previous research, hypoallergenic and elemental feeds were well tolerated in children with malnutrition and associated with improved weight gain<sup>26,27</sup>. However, assessment of impact in these studies was limited to nutritional recovery and did not assess effects on intestinal inflammation and other biomarkers of gut health. Also, recruitment in one study was limited to children who also had persistent diarrhoea<sup>26</sup>.

The concentration of calprotectin in faeces, a non-specific biomarker of intestinal inflammation, is validated in the diagnosis and management of inflammatory bowel disease<sup>28</sup>. Faecal calprotectin (FC) is markedly increased in SAM and remains elevated despite standard WHO management<sup>12,19</sup>.

Our hypothesis was that a hypoallergenic and an anti-inflammatory therapeutic formula would improve enteropathy and be well tolerated and safe in children with complicated SAM. The primary outcome was change in FC concentration. We also assessed biomarkers of intestinal integrity and systemic inflammation, tolerability of feeds, clinical outcomes and serious adverse events. Children managed with therapeutic feeds recommended by WHO formed the comparison group.

## Methods

**Study design.** This randomised, open-label, 3-arm study was conducted at “Moyo” Nutritional Rehabilitation Unit, Queen Elizabeth Central Hospital, Blantyre, Malawi in accordance with the principles of good clinical practice and the Declaration of Helsinki<sup>29</sup>. The College of Medicine Research and Ethics Committee, Blantyre, Malawi (P.06/15/1745) and the Liverpool School of Tropical Medicine Ethics Committee, Liverpool, UK (15.048) gave approval.

**Participant recruitment.** Children admitted from January 1<sup>st</sup> to December 31<sup>st</sup>, 2016 were screened for eligibility. Inclusion criteria were age 6–23 months, SAM (WHZ <−3 and/or mid-upper arm circumference (MUAC) <11.5 cms and/or nutritional oedema)<sup>30</sup>; completed the stabilisation phase of management (assessed by their usual clinician to be clinically stable and tolerating F75 therapeutic feeds)<sup>4</sup> and willing to stay on the ward for 2 weeks. We excluded children with a specific identifiable cause of malnutrition (e.g. feeding difficulties due to cerebral palsy; treatment for tuberculosis), those participating in another study or those with a sibling admitted with SAM. Both HIV positive and negative children were included. HIV positive children were already receiving ART before admission and this was continued during their care. Children were managed according to WHO guidelines using F75 therapeutic feeds during the stabilisation phase<sup>4</sup>.

Legal guardians were provided with verbal and written information either in Chichewa or English by a member of the study team. Following witnessed signed or thumbprint informed consent, research staff allocated children according to a computer-generated random sequence with blocks of random size in equal numbers to the three study arms. The legal guardian opened the next in a series of sealed, opaque envelopes each labelled with a unique study number and containing a coloured card indicating the intervention arm. Legal guardians were offered travel expenses.

**Interventions.** Children were allocated to standard feeds (ready-to-use therapeutic food (RUTF) or, if not tolerated, F100), polymeric feed (Modulen IBD; Nestlé Health Science; York, UK) or elemental feed (PurAmino; Mead Johnson Nutrition; Chicago, 606 USA). Nutriset CMV (Complex of Minerals and Vitamins) (Malaunay, France) was added to both of the alternative feeds to approximate the nutrient content of F-100 (Supplementary Table S1). All feeds were introduced gradually over 2–3 days and provided 3-hourly for 14 days. Mothers were encouraged to re-establish or continue breastfeeding. No feeds other than breastfeeding and the intervention formulas were administered. Care was according to standard Malawian practice based on WHO guidelines which included a malaria slide, blood count and an HIV rapid antibody test, chloramphenicol and gentamicin as first line and ceftriaxone as second line antibiotic therapy and withholding oral iron until discharge<sup>4</sup>. All children received standard feeds after 14 days.

**Clinical data and biological sample collection.** Demographic, anthropometric, socioeconomic and clinical information was collected at recruitment. Children were reviewed daily by the research team and volume of feed taken, symptoms reported by parents/caregivers, clinical signs and medications recorded. Research samples were collected alongside clinical samples whenever possible at recruitment, 7 and 14 days or within 48 hours of these time points. Stool samples were collected into sterile containers and transferred to a Calex tube. Up to 4 mls of venous blood was collected. 3 mls was transferred into EDTA anticoagulant and the remaining sample to a plain tube. The EDTA specimen was used to perform a full blood count by the hospital laboratory. The remaining EDTA sample and the plain tube were centrifuged and the plasma and serum, respectively, removed and

stored at  $-80^{\circ}\text{C}$  at the Malawi Liverpool Wellcome Trust laboratory, Blantyre. Further processing and analyses were undertaken within the same laboratory.

**Biomarkers of systemic and intestinal inflammation, gut integrity and growth.** Stool samples were analysed for calprotectin (Bühlmann fCAL ELISA; Schönbuch, Switzerland) as a biomarker of intestinal inflammation. Faecal  $\alpha_1$ -antitrypsin (ELISA, Immunodiagnostik AG; Hamburg, Germany), plasma intestinal fatty acid binding protein (IFABP; Human FABP2/I-FABP Quantikine ELISA Kit; R&D Systems, Inc.; Minneapolis, USA) and plasma IgG anti-endotoxin antibody concentration (EndoCab Human, ELISA; Hycult biotech; Uden, The Netherlands) were measured as markers of intestinal mucosal integrity. Plasma C-reactive protein and  $\alpha_1$ -acid glycoprotein (Quantikine ELISA, R&D Systems, Inc.; Minneapolis, USA) were measured as markers of acute and chronic systemic inflammation respectively<sup>31</sup>. Plasma insulin like growth factor (IGF)-1 and IGF binding protein 3 (IGFBP3; Quantikine ELISA, R&D Systems, Inc.; Minneapolis, USA) as growth factors that are depressed in inflammation and SAM were also measured<sup>14,32</sup>. All analyses followed the manufacturer's instructions. Normal ranges were those recommended by the manufacturers based on studies in healthy people. Laboratory staff was blinded to treatment allocations.

**Outcomes.** The primary endpoint was the change in FC during the intervention period. Secondary outcomes were change in other biomarkers, gain in weight (g/kg/day after resolution of oedema if present), diarrhoea reported by caregivers and tolerance of feeds (vomiting reported by caregivers and requirement for naso-gastric tube feeds). Suspected sepsis was defined as clinical suspicion and the start or change in antibiotic therapy by the child's clinical team. Treatment-emergent serious adverse events (SAEs), defined as events that commenced, or worsened, after the allocated feed had been administered, were reviewed by a senior paediatrician and reported to the Pharmacovigilance Pharmacist at LSTM. SAEs were reviewed by two blinded independent safety monitors and categorised according to Medical Dictionary for Regulatory Activities (MedDRA) Preferred term.

**Participant withdrawal.** Legal guardians were free to withdraw their child at any time. Participants were asked to provide an additional stool and blood sample on withdrawal from the study.

**Sample size calculation.** The geometric mean (standard deviation (SD)) for FC at recruitment in 37 malnourished Kenyan children was 2.69 (0.45); (K Jones, personal communication)<sup>19</sup>. At the 5% significance level and with a coefficient of variation of 0.4, a total of 90 children (30 in each group) was needed to detect a 25% reduction in geometric mean calprotectin in each of the alternative feed arms compared with the standard arm with at least 81% power. We intended to recruit 120 children (40/group) to allow for deaths and dropouts.

**Statistical analysis.** The effects of the therapeutic feeds were assessed according to average change from baseline in laboratory and clinical variables. The earliest and latest stool and blood samples available during the 14-day intervention period were used to assess change in biomarkers. The primary endpoint was analysed using a generalised linear model (GLM) with treatment as predictor and baseline FC as covariate. The model had Gaussian distribution and identity link function. The treatment difference in the mean of the primary outcome and its 95% CI were derived from the GLM model. Other biomarkers and clinical endpoints were analysed similarly with distributions and link functions determined by type of data (continuous, binary and count). For repeated measurement outcomes, mixed models with treatment as fixed effect, baseline measurement as covariate, and subject as random effect were used to derive treatment differences and 95% CIs. The primary endpoint analysis was based on the intention to treat (ITT) population. Additional analysis in the ITT and per protocol population of the primary and secondary endpoints were also performed. Also, data were also analysed using a t-test to detect any differences in laboratory and clinical parameters between alternative feed and standard arms at baseline (up to day 3) and day 14 ( $\pm 3$  days). No imputation was made for the outcome or baseline variables. No interim analysis was conducted. Analysis was performed using SAS v9.4.

## Results

Three hundred and sixty-seven children admitted with complicated SAM were screened. Of the 172 (46.9%) eligible children, 95 (55.2%) were randomly assigned to the three treatment arms (Fig. 1). Excluding study deviations, the number of children withdrawn by families was similar in the standard (3 children), elemental (5 children) and polymeric arms (3;  $P = 0.31$ ). Withdrawals were mostly related to family concerns with the child being enrolled in a research study and refusal to remain under admission.

Baseline demographic and clinical characteristics (Table 1) and socioeconomic factors (Supplementary Table S2) were similar in the three arms. Mean (SD) age was 15.6 (5.7) months and most children lived in either an urban or peri-urban setting. Thirty-five (36.8%) children were breastfed and all but one child was receiving complementary feeds. Mean (SD) MUAC was 10.7 cm (1.2) and WHZ in children without oedema was  $-3.74$  (1.25). Stunting was common (height-for-age z score  $-2.94$  (2.06)). Thirty-eight (40.0%) children with oedematous malnutrition were older ( $P < 0.001$ ) and had a greater mean MUAC ( $P < 0.001$ ) than those without oedema (Supplementary Table S3). Thirty-four (36.2%) children positive for HIV had a lower mean MUAC than HIV negative children ( $P = 0.002$ ; Supplementary Table S4). Children in the standard arm all received RUTF; only 6 required some F-100 during their care.

**Biomarkers.** Geometric mean values for biomarkers at baseline (within 3 days of recruitment) and day 14 ( $\pm 3$  days) according to intervention arm are shown in Fig. 2 and Supplementary Table S5. Change in biomarkers in the intervention arms versus the standard arm is shown in Table 2. At baseline, the gut, systemic inflammation and growth biomarkers were abnormal in most children with similar values in the intervention and standard arms (Fig. 2 and Supplementary Table S5).




**Figure 1.** Flowchart. Study flow diagram of children with severe acute malnutrition assessed for eligibility and recruited for the study. <sup>1</sup>Two additional children were known to have died after the 14-day study period and are not included in the Figure.

Mean FC was markedly elevated at baseline (mean (SD) 547 (744)  $\mu\text{g/g}$  stool; normal  $<50$ ) and remained elevated at 14 days (697 (735);  $P=0.31$ ; Supplementary Table S5). Change in FC was similar in the intervention versus standard arms: elemental vs. standard 4.1  $\mu\text{g/mg}$  stool/day (95% CI,  $-29.9, 38.15$ ;  $P=0.81$ ) and polymeric vs. standard 10.0 ( $-23.96, 43.91$ ;  $P=0.56$ ; Table 2).

Change in mucosal integrity biomarkers were generally similar in the intervention versus the standard arms. The exceptions were faecal  $\alpha_1$ -antitrypsin which increased significantly during treatment ( $P=0.0046$ ) and to a greater extent in the polymeric versus the standard arm ( $P=0.0013$ ) and IFABP which fell in the elemental compared with the standard arm ( $P=0.049$ ).

Change in systemic inflammation biomarkers was also generally similar in the intervention versus the standard arms. The exception was plasma  $\alpha_1$ -acid glycoprotein which fell significantly in all children ( $P<0.0001$ ) and to a greater extent in the polymeric compared with the standard arm ( $P=0.01$ ).

IGF-1 and IGFBP3 levels were low at recruitment and increased significantly during treatment ( $P<0.0001$  for both) and to a similar degree in the intervention and standard arms. Tracking changes in biomarkers in individual children did not identify subgroups of children who responded either better or worse to the interventions (Supplementary Fig. S1).

Children with oedema had a significantly higher mean plasma  $\alpha_1$ -acid glycoprotein at recruitment than those without ( $P=0.024$ ; Supplementary Table S3). HIV positive children had higher mean baseline values for FC ( $P=0.005$ ) and plasma C-reactive protein ( $P=0.008$ ) and lower haemoglobin ( $P=0.007$ ) than HIV negative children (Supplementary Table S4).

**Nutritional recovery and clinical outcomes.** Weight gain and change in MUAC and weight-for-length z score were similar in the intervention arms versus the standard arm (Table 2; Fig. 3). The number of days to resolution of oedema was similar in the standard, elemental and polymeric arms (mean (SD): 2.38 (1.12); 2.42 (1.44); 2.0 (1.12) respectively). Loose or watery stools were very common in all three arms (Supplementary Table S6). The alternative feeds were tolerated less well than standard feeds (mostly RUTF) with greater requirement for

| Variable <sup>a</sup>                                    | Standard<br>N = 31 | Elemental<br>N = 32 | Polymeric N = 32       | Total N = 95 |
|----------------------------------------------------------|--------------------|---------------------|------------------------|--------------|
| <b>Demographic variables</b>                             |                    |                     |                        |              |
| Age in months (mean; SD)                                 | 16.6 (5.4)         | 14.8 (6.6)          | 15.5 (5.2)             | 15.6 (5.74)  |
| Male                                                     | 14 (45.2)          | 15 (46.9)           | 17 (53.1)              | 46 (48.4)    |
| Residence type                                           |                    |                     |                        |              |
| Rural                                                    | 10 (32.3)          | 9 (28.1)            | 10 (31.3)              | 29 (30.5)    |
| Urban                                                    | 14 (45.2)          | 19 (59.4)           | 17 (53.1)              | 50 (52.6)    |
| Peri-urban                                               | 7 (22.6)           | 4 (12.5)            | 5 (15.6)               | 16 (16.8)    |
| Mother main caregiver                                    | 30 (96.8)          | 29 (90.6)           | 27 (84.4)              | 86 (90.5)    |
| Mother HIV positive                                      | 10 (37)            | 14 (43.8)           | 14 (43.8)              | 38 (40)      |
| Mother died                                              | 1 (3.2)            | 1 (3.1)             | 2 (6.3)                | 4 (4.2)      |
| Number of siblings alive (mean; SD)                      | 1.87 (1.5)         | 1.78 (1.5)          | 1.13 (1.3)             | 1.59 (1.45)  |
| Number of siblings died (mean; SD)                       | 0.19 (0.5)         | 0.13 (0.42)         | 0.41 (1.0)             | 0.24 (0.70)  |
| <b>Clinical variables</b>                                |                    |                     |                        |              |
| Child HIV positive                                       | 11 (35.5)          | 12 (37.5)           | 11 (34.4) <sup>b</sup> | 34 (35.8)    |
| Breastfed                                                | 22 (71)            | 20 (62.5)           | 20 (62.5)              | 62 (65.3)    |
| Receiving complementary feeds                            | 31 (100)           | 31 (96.9)           | 32 (100)               | 94 (98.9)    |
| Oedema                                                   |                    |                     |                        |              |
| None                                                     | 17 (54.8)          | 18 (56.3)           | 22 (68.8)              | 57 (60)      |
| +                                                        | 4 (12.9)           | 3 (9.38)            | 3 (9.38)               | 10 (10.5)    |
| ++                                                       | 5 (16.1)           | 9 (28.1)            | 6 (18.8)               | 20 (21.1)    |
| +++                                                      | 5 (16.1)           | 2 (6.25)            | 1 (3.13)               | 8 (8.42)     |
| Mid upper arm circumference (cms; mean; SD) <sup>c</sup> | 10.3 (1.2)         | 10.5 (1.27)         | 11.3 (0.81)            | 10.7 (1.2)   |
| Weight-for-height z score (mean; SD) <sup>d</sup>        | −4.10 (1.34)       | −3.79 (1.28)        | −3.41 (1.13)           | −3.74 (1.25) |
| Length-for-age z score (mean; SD)                        | −2.80 (1.49)       | −3.01 (2.85)        | −3.00 (1.60)           | −2.94 (2.06) |

**Table 1.** Baseline demographic and clinical characteristics according to intervention arm. <sup>a</sup>Values are number (%) unless otherwise stated; <sup>b</sup>HIV status not known for 1 child; <sup>c</sup>Only reported for children without severe oedema (+++, ++++); <sup>d</sup>Only reported for children without oedema.

nasogastric tube (NGT) feeding and caregiver reporting of vomiting. In addition, amongst those affected, vomiting occurred more frequently with the elemental compared with standard feeds (average difference = 2.22/day, 95% CI = 1.08, 4.58;  $P = 0.031$ ). However, reverting back to F75 was not required with the polymeric feed (Supplementary Table S6). The number of days with loose stools and vomiting amongst children who experienced these symptoms was similar in each arm.

When HIV status or oedema at recruitment were included in the GLM, there was no evidence of interaction between treatment arm and changes in clinical or laboratory outcomes except that plasma  $\alpha_1$ -acid glycoprotein fell to greater degree in children with oedema than those without ( $P = 0.025$ ).

**Serious adverse events and deaths.** A total of 43 SAEs occurred in 25 (27.4%) children with a similar frequency in each arm ( $P = 0.5$ ; Supplementary Table S7). The most frequent SAEs were gastroenteritis (13.7% children), dehydration (11.6%) and sepsis (6.3%). Gastroenteritis and dehydration in two children and an urticarial rash in one child were considered possibly related to the therapeutic feeds and all occurred in the standard arm. Seven children died (7.4%) within the 14-day study period; 5 deaths (71%) occurred in HIV positive children and 3 (43%) in children with oedema. Another two children died on day 15 with death attributed to a SAE that started within the study period; both of these children were in the standard arm. The number of deaths was similar in each intervention arm (Supplementary Table S7).

## Discussion

This study confirms previous observations that compromised gut integrity and intestinal and systemic inflammation occur in complicated SAM. Despite moderate weight gain and a rise in growth factors in all three arms, biomarkers of intestinal pathology did not improve during 14 days treatment either with standard or the alternative therapeutic feeds. The biomarker findings are consistent with the on-going or recurrent diarrhoea in many children and the persistence of histological abnormalities despite treatment reported previously<sup>16</sup>. The persistence of the gut pathology likely contributes to the 10–30% case-fatality<sup>6,12,33–37</sup>, with even higher mortality in HIV positive children<sup>8,38</sup>, and also poor longer-term outcomes with mortality after hospital discharge typically around 25%<sup>8,10</sup>.

The degree of intestinal inflammation in our children with complicated SAM based on FC concentrations are similar to that observed in Crohn's disease<sup>28</sup>. Severely impaired mucosal integrity in our children was evidenced by marked abnormalities in three biomarkers. Levels of plasma I-FABP, reflecting enterocyte destruction<sup>39</sup>, were similar to those in south African children with SAM<sup>40</sup>, active Crohn's disease<sup>41</sup> and greater than those reported in adults with acute mesenteric ischemia<sup>42,43</sup>. Faecal  $\alpha_1$ -antitrypsin, a biomarker of intestinal protein loss and




**Figure 2.** Biomarkers according to intervention arm. Box plots show values at baseline (or up to day 3) and day 14 ( $\pm 3$  days) according to intervention group (standard: blue, elemental: red, polymeric: green). Boxplots summarise the median (midline), the mean (diamond marker) and interquartile ranges (upper and lower box). Whiskers are drawn to the nearest value within 1.5 times the IQR. Values outside of this range are shown as circles. Light blue shading shows normal range.

moderately increased in our patients, is also elevated in Crohn's disease<sup>44</sup>. Finally, anti-endotoxin antibodies in plasma likely indicates translocation of gut bacteria<sup>40</sup>.

Significant systemic inflammation at recruitment was evidenced by raised CRP, platelet count and plasma  $\alpha_1$ -acid glycoprotein consistent with findings in inflammatory bowel disease<sup>45</sup>. Although plasma  $\alpha_1$ -acid

| Variable                                                  | Elemental vs Standard |                       |         | Polymeric vs Standard |                       |         |
|-----------------------------------------------------------|-----------------------|-----------------------|---------|-----------------------|-----------------------|---------|
|                                                           | N <sup>b</sup>        | Change/day (95% CI)   | P value | N <sup>c</sup>        | Change/day (95% CI)   | P value |
| <b>Intestinal inflammation</b>                            |                       |                       |         |                       |                       |         |
| Faecal calprotectin ( $\mu\text{g/g}$ stool)              | 26/25                 | 4.1 (−29.9, 38.2)     | 0.81    | 26/25                 | 10 (−24.0, 43.9)      | 0.56    |
| <b>Intestinal integrity</b>                               |                       |                       |         |                       |                       |         |
| Faecal $\alpha_1$ -antitrypsin (mg/dl)                    | 21/23                 | 1.7 (−0.42, 3.8)      | 0.12    | 22/23                 | 3.5 (1.4, 5.5)        | 0.0013  |
| Plasma IgG anti-endotoxin antibodies (GMU/ml)             | 16/18                 | −1.8 (−11.8, 8.3)     | 0.72    | 17/18                 | −2.1 (−11.7, 7.5)     | 0.66    |
| Plasma Intestinal fatty acid binding protein (pg/ml)      | 16/17                 | −194.3 (−387.6, −1.0) | 0.05    | 17/17                 | −83.8 (−276.2, 108.5) | 0.38    |
| <b>Systemic inflammation</b>                              |                       |                       |         |                       |                       |         |
| Platelets ( $\times 10^9/\text{L}$ blood)                 | 15/19                 | 7.4 (−9.1, 23.9)      | 0.37    | 17/19                 | −7.1 (−23.0, 8.9)     | 0.38    |
| Plasma C-reactive protein (mg/L)                          | 16/17                 | −0.7 (−2.2, 0.81)     | 0.35    | 17/17                 | −0.04 (−1.55, 1.046)  | 0.95    |
| Plasma $\alpha_1$ -acid glycoprotein ( $\mu\text{g/ml}$ ) | 16/16                 | −15.7 (−84.8, 53.4)   | 0.65    | 17/16                 | −89.4 (−157.7, 21.1)  | 0.01    |
| <b>Growth Factors</b>                                     |                       |                       |         |                       |                       |         |
| Insulin-like growth factor −1 (ng/ml)                     | 9/9                   | 4.4 (−2.1, 10.9)      | 0.17    | 14/9                  | 4.3 (−1.3, 9.9)       | 0.13    |
| Insulin-like growth factor binding; protein 3 (ng/ml)     | 16/17                 | 22.3 (−29.7, 74.4)    | 0.39    | 17/17                 | 37.1 (−14.1, 88.3)    | 0.15    |
| <b>Clinical</b>                                           |                       |                       |         |                       |                       |         |
| Weight (g/kg/day)                                         | 30/30                 | 1.6 (−3.6, 6.8)       | 0.54    | 31/30                 | 2.5 (−2.1, 7.7)       | 0.33    |
| MUAC (cms/day)                                            | 31/30                 | 0.025 (−0.025, 0.07)  | 0.32    | 32/30                 | 0.042 (−0.009, 0.09)  | 0.1     |
| Weight-for-length z-score                                 | 30/30                 | 0.22 (−0.29, 0.76)    | 0.39    | 31/30                 | 0.19 (−0.31, 0.7)     | 0.45    |

**Table 2.** Change in laboratory biomarkers and clinical variables according to intervention arm<sup>a</sup>. <sup>a</sup>Data are number of children and generalised linear analysis of mean (95% CI) difference in change in variable/day in the alternative feed compared to standard feed. A negative value signifies a fall in the variable with the alternative therapeutic feed compared with standard feeds and *vice versa* for a positive value. Laboratory measurements were made in the first and last samples available and clinical measurements on recruitment and the last measurement available during the 14-day intervention period. <sup>b</sup>Numbers represent the data available for the elemental/standard treatment group. <sup>c</sup>Numbers represent the data available for the polymeric/standard treatment group. MUAC, mid-upper arm circumference.




**Figure 3.** Anthropometry according to intervention arm. Box plots show parameter at baseline (or up to day 3) and day 14 ( $\pm 3$  days) according to intervention group (standard: blue, elemental: red, polymeric: green) and show the median (midline), the mean (diamond marker) and interquartile ranges (upper and lower box). Whiskers are drawn to the nearest value within 1.5 times the IQR. Values outside of this range are shown as circles.

glycoprotein, a biomarker of chronic inflammation, fell significantly during treatment, platelet counts increased and abnormal levels for all three biomarkers persisted in most children. In complicated SAM, systemic inflammation may result from infections, including translocation of gut bacteria<sup>40</sup>, as well as intestinal inflammation<sup>12</sup>. The fall in plasma  $\alpha_1$ -acid glycoprotein may reflect treatment of systemic infection rather than reduced intestinal inflammation.

The failure of the two alternative feeds to improve intestinal pathology, systemic inflammation or clinical outcomes contrasts markedly with their clinical efficacy in non-IgE mediated food allergy<sup>20,21</sup> and Crohn's disease. In

the latter, although the mechanism is unknown, exclusive enteral nutrition with either a polymeric or elemental formula reduces intestinal inflammation, promotes mucosal healing, down regulates pro-inflammatory cytokines and improves nutritional status<sup>16–19</sup>. Although we observed a greater fall in plasma  $\alpha_1$ -acid glycoprotein in the polymeric arm, possibly related to its content of transforming growth factor beta<sup>46</sup>, in the absence of a similar effect on other biomarkers of systemic inflammation and an increase in faecal  $\alpha_1$ -antitrypsin with the polymeric feed, the clinical relevance of this finding is unclear. The greater fall in IFABP in the elemental compared with the standard group was of borderline statistical significance and, in the absence of associated clinical benefits, is unlikely to be of clinical significance. The lack of efficacy of the elemental formula indicates that exclusion of dietary antigens present in either cow milk based therapeutic feeds or RUTF is not effective in improving enteropathy. The discrepancy between our findings with older studies of elemental formula which reported improved weight gain in malnourished children with diarrhoea<sup>26,27</sup> may be due to differences in the patient population or the use of RUTF as standard treatment in our study.

The higher  $\alpha_1$ -acid glycoprotein at recruitment in oedematous children may reflect greater bacterial translocation consistent with impaired intestinal integrity related to deficient glycosylation reported in kwashiorkor<sup>17</sup>. However, anti-endotoxin antibodies and other markers of gut integrity did not differ significantly according to presence of oedema. CRP and FC were particularly elevated in HIV positive children at recruitment, the latter consistent with findings in HIV infected Zambian children with SAM and persistent diarrhoea<sup>14</sup>. However, biomarkers of mucosal integrity did not differ significantly according to HIV status. This has also been reported in South African children with SAM in whom plasma IFABP and also plasma 16sDNA as a marker of microbial translocation were similar in those with and without HIV<sup>40</sup>. The contribution of HIV to the enteropathy in complicated SAM requires further study.

Our study had several limitations. We recruited only 55% of eligible children which limits the generalisability of our findings. Sample collection was difficult in these sick children who are already having samples collected for clinical purposes. This limited the number of samples available for the measurement of several of the biomarkers and risks a false negative result that incorrectly rejects a useful intervention. However, the findings across the clinical and laboratory variables did not suggest a trend towards a beneficial effect of either of the two intervention feeds compared with standard feeds. In this open study, reporting of symptoms and clinical observations could have been biased. However, measurement of biomarkers was blinded and these findings were consistent with the non-blinded observations. Finally, although exclusive enteral nutrition with a polymeric formula in Crohn's disease reduced systemic inflammation within 3–14 days<sup>47–49</sup>, and guidelines recommend that an alternative therapy should be considered if a clinical response has not occurred within 2 weeks<sup>50</sup>, it is possible that feeding for longer than 14 days may have improved outcomes in our cases. However, in our setting, longer periods of exclusive enteral nutrition would be impractical given their poorer tolerance than RUTF, greater requirement for NGT feeding and likely need for prolonged hospital admission to supervise feeding which also carries the risk of increased exposure to hospital acquired infections.

We are not aware of any previous studies of interventions for enteropathy in children with complicated SAM. In a previous study on the Moyo ward, a synbiotic supplement did not improve clinical outcomes<sup>51</sup>.

Our findings that neither the elemental nor polymeric feeds administered for up to 14 days resulted in any clear improvement in biomarkers of intestinal inflammation and integrity, systemic inflammation or clinical benefit in complicated SAM suggests multifactorial intestinal pathology. The enteropathy in complicated SAM may be a continuum of environmental enteric dysfunction (EED) that is ubiquitous in unhygienic settings<sup>13</sup>. Recent studies of EED have highlighted the critical importance of sub-clinical infection with enteropathogens in compromising mucosal integrity and causing intestinal and systemic inflammation<sup>52</sup> and the high burden of gut pathogens in complicated SAM was associated with intestinal inflammation<sup>12</sup>. Targeting enteropathogens in complicated SAM may be required to improve the enteropathy.

## Conclusions

Current WHO management fails to improve intestinal pathology in complicated SAM. Elemental and polymeric feeds did not have the hoped anti-inflammatory or clinical benefits and proved to be poorly tolerated. Further research is needed to better understand the intestinal pathology in complicated SAM to help develop interventions that may address the unacceptably high case-fatality and poor long-term outcomes.

## Data Availability

The datasets generated during this study will be available from the corresponding author on reasonable request.

## References

1. Black, R. E. *et al.* Maternal and child undernutrition and overweight in low-income and middle-income countries. *Lancet* **382**, 427–451 (2013).
2. Institute, I. F. P. R. *International Food Policy Research Institute Global Nutrition Report 2016: From Promise to Impact: Ending Malnutrition by 2030* (2016).
3. United Nations Children's Fund, W. H., Group, O. & W. B. Joint child malnutrition estimates 2017. Available at, <http://apps.who.int/gho/data/node.wrapper.nutrition-2016> (2017).
4. WHO. *Guideline: Updates on the management of severe acute malnutrition in infants and children*. World Health Organization (World Health Organization, 2013).
5. Lenters, L. M., Wazny, K., Webb, P., Ahmed, T. & Bhutta, Z. A. Treatment of severe and moderate acute malnutrition in low- and middle-income settings: a systematic review, meta-analysis and Delphi process. *BMC Public Health* **13**, S23 (2013).
6. Heikens, G. T. *et al.* Case management of HIV-infected severely malnourished children: challenges in the area of highest prevalence. *Lancet* **371**, 1305–1307 (2008).
7. Bartels, R. H. *et al.* Both Exocrine Pancreatic Insufficiency and Signs of Pancreatic Inflammation Are Prevalent in Children with Complicated Severe Acute Malnutrition: An Observational Study. *J. Pediatr.* **174**, 165–170 (2016).

8. Kerac, M. *et al.* Follow-up of post-discharge growth and mortality after treatment for severe acute malnutrition (FuSAM study): a prospective cohort study. *PLoS One* **9**, e96030 (2014).
9. Bartels, R. H. *et al.* Pancreatic Enzyme Replacement Therapy in Children with Severe Acute Malnutrition: A Randomized Controlled Trial. *J. Pediatr.* **190**, 85–92.e2 (2017).
10. Berkley, J. A. *et al.* Daily co-trimoxazole prophylaxis to prevent mortality in children with complicated severe acute malnutrition: a multicentre, double-blind, randomised placebo-controlled trial. *Lancet. Glob. Heal.* **4**, e464–73 (2016).
11. Campbell, D. I. *et al.* Chronic T cell-mediated enteropathy in rural west African children: relationship with nutritional status and small bowel function. *Pediatr. Res.* **54**, 306–11 (2003).
12. Attia, S. *et al.* Mortality in children with complicated severe acute malnutrition is related to intestinal and systemic inflammation: an observational cohort study. *Am. J. Clin. Nutr.* **104**, 1441–1449 (2016).
13. Prendergast, A. & Kelly, P. Enteropathies in the developing world: neglected effects on global health. *Am. J. Trop. Med. Hyg.* **86**, 756–63 (2012).
14. Amadi, B. *et al.* Impaired Barrier Function and Autoantibody Generation in Malnutrition Enteropathy in Zambia. *EBioMedicine* **22**, 191–199 (2017).
15. Bhutta, Z. A. *et al.* Severe childhood malnutrition. *Nat. Rev. Dis. Prim.* **3**, 17067 (2017).
16. Sullivan, P. B. *et al.* Persistent diarrhea and malnutrition—the impact of treatment on small bowel structure and permeability. *J. Pediatr. Gastroenterol. Nutr.* **14**, 208–215 (1992).
17. Amadi, B. *et al.* Reduced production of sulfated glycosaminoglycans occurs in Zambian children with kwashiorkor but not marasmus. *Am. J. Clin. Nutr.* **89**, 592–600 (2009).
18. Brewster, D. R., Manary, M. J., Menzies, I. S., O'Loughlin, E. V. & Henry, R. L. Intestinal permeability in kwashiorkor. *Arch. Dis. Child.* **76**, 236–41 (1997).
19. Jones, K. D. J. *et al.* Mesalazine in the initial management of severely acutely malnourished children with environmental enteric dysfunction: a pilot randomized controlled trial. *BMC Med.* **12**, 133 (2014).
20. Crittenden, R. G. & Bennett, L. E. Cow's milk allergy: a complex disorder. *J. Am. Coll. Nutr.* **24**, 582S–91S (2005).
21. Caubet, J.-C., Szajewska, H., Shamir, R. & Nowak-Węgrzyn, A. Non-IgE-mediated gastrointestinal food allergies in children. *Pediatr. Allergy Immunol.* **28**, 6–17 (2017).
22. Mayberry, J. F., Lobo, A., Ford, A. C. & Thomas, A. NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people. *Aliment. Pharmacol. Ther.* **37**, 195–203 (2013).
23. Hartman, C., Eliakim, R. & Shamir, R. Nutritional status and nutritional therapy in inflammatory bowel diseases. *World J. Gastroenterol.* **15**, 2570–8 (2009).
24. Ludvigsson, J. F., Krantz, M., Bodin, L., Stenhammar, L. & Lindquist, B. Elemental versus polymeric enteral nutrition in paediatric Crohn's disease: a multicentre randomized controlled trial. *Acta Paediatr.* **93**, 327–35 (2004).
25. Dziechciarz, P., Horvath, A., Shamir, R. & Szajewska, H. Meta-analysis: Enteral nutrition in active Crohn's disease in children. *Aliment. Pharmacol. Ther.* **26**, 795–806 (2007).
26. Amadi, B. *et al.* Improved nutritional recovery on an elemental diet in Zambian children with persistent diarrhoea and malnutrition. *J. Trop. Pediatr.* **51**, 5–10 (2005).
27. Eichenberger, J. R., Hadorn, B. & Schmidt, B. J. A semi-elemental diet with low osmolality and high content of hydrolyzed lactalbumin in the treatment of acute diarrhea in malnourished children. *Arg. Gastroenterol.* **21**, 130–5 (1984).
28. Henderson, P., Anderson, N. H. & Wilson, D. C. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. *Am. J. Gastroenterol.* **109**, 637–45 (2014).
29. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA* **310**, 2191–2194 (2013).
30. WHO *et al.* WHO child growth standards and the identification of severe acute malnutrition in infants and children. WHO (World Health Organization, 2009).
31. Thurnham, D. I. *et al.* Adjusting plasma ferritin concentrations to remove the effects of subclinical inflammation in the assessment of iron deficiency: a meta-analysis. *Am. J. Clin. Nutr.* **92**, 546–555 (2010).
32. DeBoer, M. D. *et al.* Systemic inflammation, growth factors, and linear growth in the setting of infection and malnutrition. *Nutrition* **33**, 248–253 (2017).
33. Tickell, K. D. & Denno, D. M. Inpatient management of children with severe acute malnutrition: a review of WHO guidelines. *Bull. World Health Organ.* **94**, 642–651 (2016).
34. Ahmed, T. *et al.* Mortality in severely malnourished children with diarrhoea and use of a standardised management protocol. *Lancet (London, England)* **353**, 1919–1922 (1999).
35. Irena, A. H., Mwambazi, M. & Mulenga, V. Diarrhea is a major killer of children with severe acute malnutrition admitted to inpatient set-up in Lusaka, Zambia. *Nutr J* **10**, 110 (2011).
36. Talbert, A. *et al.* Diarrhoea complicating severe acute malnutrition in Kenyan children: a prospective descriptive study of risk factors and outcome. *PLoS One* **7**, e38321 (2012).
37. Maitland, K. *et al.* Children with severe malnutrition: can those at highest risk of death be identified with the WHO protocol? *PLoS Med.* **3**, e500 (2006).
38. Fergusson, P., Tomkins, A. & Kerac, M. Improving survival of children with severe acute malnutrition in HIV-prevalent settings. *Int. Health* **1**, 10–16 (2009).
39. Piton, G. & Capellier, G. Biomarkers of gut barrier failure in the ICU. *Curr. Opin. Crit. Care* **22**, 152–60 (2016).
40. Muenchhoff, M. *et al.* Malnutrition in HIV-infected children is an indicator of severe disease with an impaired response to antiretroviral therapy. *AIDS. Res. Hum. Retroviruses* **AID.2016.0261**, <https://doi.org/10.1089/AID.2016.0261> (2017).
41. Sarikaya, M. *et al.* Intestinal fatty acid binding protein (I-FABP) as a promising test for Crohn's disease: a preliminary study. *Clin. Lab.* **61**, 87–91 (2015).
42. Kanda, T. *et al.* Diagnosis of ischemic small bowel disease by measurement of serum intestinal fatty acid-binding protein in patients with acute abdomen: a multicenter, observer-blinded validation study. *J. Gastroenterol.* **46**, 492–500 (2011).
43. Güzel, M. *et al.* The value of the serum I-FABP level for diagnosing acute mesenteric ischemia. *Surg. Today* **44**, 2072–2076 (2014).
44. Sutherland, A. D., Gearry, R. B. & Frizelle, F. A. Review of fecal biomarkers in inflammatory bowel disease. *Dis. Colon Rectum* **51**, 1283–91 (2008).
45. Fengming, Y. & Jianbing, W. Biomarkers of inflammatory bowel disease. *Dis. Markers* **2014**, 710915 (2014).
46. Hartman, C. *et al.* Nutritional supplementation with polymeric diet enriched with transforming growth factor-beta 2 for children with Crohn's disease. *Isr. Med. Assoc. J.* **10**, 503–7 (2008).
47. Fell, J. M. *et al.* Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. *Aliment. Pharmacol. Ther.* **14**, 281–9 (2000).
48. Bannerjee, K. *et al.* Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. *J. Pediatr. Gastroenterol. Nutr.* **38**, 270–5 (2004).
49. Borrelli, O. *et al.* Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. *Clin. Gastroenterol. Hepatol.* **4**, 744–53 (2006).
50. Ruemmele, F. M. *et al.* Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. *J. Crohn's Colitis* **8**, 1179–1207 (2014).

51. Kerac, M. *et al.* Probiotics and prebiotics for severe acute malnutrition (PRONUT study): a double-blind efficacy randomised controlled trial in Malawi. *Lancet* **374**, 136–144 (2009).
52. Kosek, M. *et al.* Assessment of environmental enteropathy in the MAL-ED cohort study: Theoretical and analytic framework. *Clin. Infect. Dis.* **59** (2014).
53. Bartels, R. H. Children with Severe Acute Malnutrition: new diagnostic and treatment strategies (University of Amsterdam, 2018).

## Acknowledgements

We thank the staff of the Moyo NRU for their great support for the project. We thank Cheryl Pace, Pharmacovigilance Pharmacist at LSTM for reviewing and reporting SAE data and Julian Thomas and Anne Dale in their role as external safety monitors. We thank André Briend for advice on preparation of the alternative therapeutic feeds. We thank Mead Johnson Nutrition for donating the PurAmino Infant Formula and Nutriset for donating Therapeutic CMV. Finally, we thank the children and their families who agreed to participate in the study. We would like to acknowledge that a previous version of this paper was included in the PhD thesis of the first author of this manuscript<sup>53</sup>. Donations of materials for use in the trial were received from Mead Johnson Nutrition and Nutriset. However, neither company had any involvement in the conduct of the trial or in the analysis and reporting of the findings. This work was supported by a MRC/DfID/Wellcome Global Health Trials Development Grant [grant number MR/M022390/1].

## Author Contributions

R.H.B. and S.A. wrote the initial draft and all authors contributed to and approved the manuscript. Professional writers were not used. S.A., W.V. and R.H.J.B. designed the study. S.A. was the principal investigator. R.H.B. was the lead study clinician in Malawi. Q.D. and R.H.B. reviewed children with serious adverse events. E.C. supervised data collection and management. I.P. supervised the research and clinical staff on the Moyo NRU. B.A. led on clinical review and data collection from participants. K.C. and A.A. supervised sample collection, processing and storage. D.W. developed the statistical analysis plan and led on data analysis. V.W., L.P. and R.H.B. analysed the data and designed tables and figures. S.A., A.A., Q.D., M.M., R.H.J.B. and W.V. provided senior supervision and support for the project.

## Additional Information

**Supplementary information** accompanies this paper at <https://doi.org/10.1038/s41598-019-38690-9>.

**Competing Interests:** The authors declare no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019

## **TITLE PAGE**

### **1. Title**


**Hypoallergenic and anti-inflammatory feeds in children with complicated severe acute malnutrition: an open randomised controlled 3-arm intervention trial in Malawi**

### **2. Author Names**


Rosalie H. Bartels (PhD)<sup>1,2\*</sup>, Emmanuel Chimwezi (BSc)<sup>2,3</sup>, Victoria Watson (BSc)<sup>4</sup>, Leilei Pei (PhD)<sup>4</sup>, Isabel Potani (MSc)<sup>2</sup>, Benjamin Allubha (BSc)<sup>2</sup>, Kate Chidzalo (BSc)<sup>2,3</sup>, Duolao Wang (PhD)<sup>4</sup>, Queen Dube (PhD)<sup>5</sup>, Macpherson Mallewa (PhD)<sup>5</sup>, Angela Allen (PhD)<sup>6</sup>, Robert H.J. Bandsma (PhD)<sup>3,7,8,9</sup>, Wieger P. Voskuijl (PhD)<sup>1,2,3</sup>, Stephen J Allen (MD)<sup>4</sup>

## Supplementary Figure


### Supplementary Figure S1 – Changes in biomarkers in individual children according to intervention arm




Supplementary Figure



## Supplementary Figure



## Supplementary Figure



Light blue shading shows normal range.

## **TITLE PAGE**

### **1. Title**

**Hypoallergenic and anti-inflammatory feeds in children with complicated severe acute malnutrition: an open randomised controlled 3-arm intervention trial in Malawi**

### **2. Author Names**

Rosalie H. Bartels (PhD)<sup>1,2\*</sup>, Emmanuel Chimwezi (BSc)<sup>2,3</sup>, Victoria Watson (BSc)<sup>4</sup>, Leilei Pei (PhD)<sup>4</sup>, Isabel Potani (MSc)<sup>2</sup>, Benjamin Allubha (BSc)<sup>2</sup>, Kate Chidzalo (BSc)<sup>2,3</sup>, Duolao Wang (PhD)<sup>4</sup>, Queen Dube (PhD)<sup>5</sup>, Macpherson Mallewa (PhD)<sup>5</sup>, Angela Allen (PhD)<sup>6</sup>, Robert H.J. Bandsma (PhD)<sup>3,7,8,9</sup>, Wieger P. Voskuijl (PhD)<sup>1,2,3</sup>, Stephen J Allen (MD)<sup>4</sup>

Supplementary Table S1 – Composition of therapeutic feeds per litre

| Nutrient              | RUTF<br>(Per sachet<br>of 92g) | F-100 <sup>1</sup> | Modulen<br>IBD <sup>2,3</sup> with<br>1.7g CMV/L | PurAmino <sup>2,4,5</sup><br>with 1.7g<br>CMV/L |
|-----------------------|--------------------------------|--------------------|--------------------------------------------------|-------------------------------------------------|
| Energy (kcal)         | 500                            | 998                | 1000                                             | 1000                                            |
| Protein (g)           | 12.5                           | 29                 | 36                                               | 27.8                                            |
| Carbohydrates (g)     |                                | 50                 | 110                                              | 105.9                                           |
| Fat (g)               | 32.86                          | 59                 | 47                                               | 52.9                                            |
| Osmolality (mOsmol/l) |                                | 419                | 290                                              | 450.6                                           |
| <b>Minerals</b>       |                                |                    |                                                  |                                                 |
| Sodium (mg)           | < 267                          | 560                | 350.0                                            | 470.6                                           |
| Potassium (mg)        | 1022                           | 2300               | 1782.3                                           | 1670.5                                          |
| Calcium (mg)          | 276                            | 850                | 910.0                                            | 941.2                                           |
| Phosphorus (mg)       | 276                            | 825                | 610.0                                            | 514.7                                           |
| Magnesium (mg)        | 84.6                           | 154                | 263.3                                            | 172.1                                           |
| Zinc (mg)             | 12.9                           | 21.2               | 21.6                                             | 22.0                                            |
| Copper (mg)           | 1.6                            | 3                  | 2.5                                              | 2.3                                             |
| Iron (mg)             | 10.6                           | 0.4                | 11.0                                             | 17.9                                            |
| Manganese (mg)        | -                              | -                  | 2                                                | -                                               |
| Fluoride (µg)         | -                              | -                  | <20                                              | -                                               |
| Chromium (µg)         | -                              | -                  | 51                                               | -                                               |
| Molybdenum (µg)       | -                              | -                  | 75                                               | -                                               |
| Selenium (µg)         | 27.6                           | 57                 | 35.0                                             | 27.8                                            |
| Iodine (µg)           | 92                             | 225                | 100.1                                            | 148.6                                           |
| <b>Vitamins</b>       |                                |                    |                                                  |                                                 |
| A µg RE               | 840                            | 1544               | 1911.0                                           | 1968.1                                          |
| D µg                  | 15                             | 29                 | 27.0                                             | 29.5                                            |
| E mg α-TE             | 18.4                           | 38.6               | 32.4                                             | 32.8                                            |
| K µg                  | 19.3                           | 29                 | 76.3                                             | 111.0                                           |
| C mg                  | 49                             | 96.5               | 145.5                                            | 167.6                                           |
| B1 (Thiamin) mg       | 0.55                           | 0.97               | 1.7                                              | 1.3                                             |
| B2 (Riboflavin) mg    | 1.66                           | 3.1                | 2.8                                              | 2.4                                             |
| Pantothenic acid mg   | 2.85                           | 5.8                | 8.0                                              | 8.0                                             |
| B6 mg                 | 0.55                           | 1.2                | 2.3                                              | 1.2                                             |
| B12 µg                | 1.7                            | 3.1                | 4.7                                              | 4.5                                             |
| Niacin mg             | 4.88                           | 9.7                | 16.8                                             | 14.8                                            |
| Folic acid µg         | 193                            | 386                | 435.5                                            | 354.3                                           |
| Biotin µg             | 60                             | 116                | 89.8                                             | 87.2                                            |

- For composition, see: <http://apps.who.int/iris/bitstream/10665/41999/1/a57361.pdf>  
Both feeds were prepared by adding cooled, boiled water to 400g to make-up to 2L and then adding 1.7g CMV (Complex of Minerals and Vitamins)/L
- For composition, see: <https://www.nestlehealthscience.co.uk/asset-library/documents/data%20card%20modulen%20ibd.pdf>
- For composition, see: [http://www.nutramigen.co.uk/files/5114/2565/5560/Filofax\\_Puramino\\_01\\_2015\\_5.pdf](http://www.nutramigen.co.uk/files/5114/2565/5560/Filofax_Puramino_01_2015_5.pdf)
- Prepared as described results in a formula with approx. 1kcal/ml  
(<http://www.meadjohnson.com/pediatrics/us-en/sites/hcp-usa/files/345%20PurAmino%20Scoop%20Dilution.pdf>)  
RUTF, ready-to-use therapeutic food.

Supplementary Table S2 – **Socioeconomic variables at recruitment according to intervention arm**

| <b>Variable N (%)</b>                                     | <b>Standard<br/>(N=31)</b> | <b>Elemental<br/>(N=32)</b> | <b>Polymeric<br/>(N=32)</b> | <b>Total<br/>(N=95)</b> |
|-----------------------------------------------------------|----------------------------|-----------------------------|-----------------------------|-------------------------|
| House type                                                |                            |                             |                             |                         |
| • Owned                                                   | 12 (38.7)                  | 19 (59.4)                   | 13 (40.6)                   | 44 (46.3)               |
| • Rented                                                  | 19 (61.3)                  | 12 (37.5)                   | 18 (56.3)                   | 49 (51.6)               |
| • Other                                                   | 0 (0.0)                    | 1 (3.13)                    | 1 (3.13)                    | 2 (2.11)                |
| Number sleeping rooms (mean; SD)                          | 1.97 (0.71)                | 2.56 (1.29)                 | 2.13 (0.91)                 | 2.22 (1.02)             |
| Number of people usually sleeping in the house (mean; SD) | 4.61 (1.84)                | 4.66 (1.77)                 | 4.81 (2.05)                 | 4.69 (1.87)             |
| Electricity supply                                        | 8 (25.8)                   | 10 (31.3)                   | 5 (15.6)                    | 23 (24.2)               |
| The family owns:                                          |                            |                             |                             |                         |
| • A radio                                                 | 11 (35.5)                  | 16 (50)                     | 10 (31.3)                   | 37 (38.9)               |
| • A bicycle                                               | 2 (6.45)                   | 5 (15.6)                    | 4 (12.5)                    | 11 (11.6)               |
| • A motorbike                                             | 0 (0.0)                    | 1 (3.13)                    | 1 (3.13)                    | 2 (2.11)                |
| • A car or truck                                          | 1 (3.23)                   | 0 (0.0)                     | 0 (0.0)                     | 1 (1.05)                |
| • A paraffin lamp                                         | 7 (22.6)                   | 10 (31.3)                   | 8 (25)                      | 25 (26.3)               |
| • A koloboyi (paraffin lamp)                              | 10 (32.3)                  | 9 (28.1)                    | 18 (56.3)                   | 37 (38.9)               |
| • An oxcart                                               | 0 (0.0)                    | 1 (3.13)                    | 0 (0.0)                     | 1 (1.05)                |
| • A television                                            | 4 (12.9)                   | 10 (31.3)                   | 3 (9.38)                    | 17 (17.9)               |
| • A cell phone                                            | 12 (38.7)                  | 14 (43.8)                   | 15 (46.9)                   | 41 (43.2)               |
| • A telephone (landline)                                  | 0 (0.0)                    | 1 (3.13)                    | 1 (3.13)                    | 2 (2.11)                |
| • A bed with mattress                                     | 12 (38.7)                  | 20 (62.5)                   | 7 (21.9)                    | 39 (41.1)               |
| • A sofa set                                              | 4 (12.9)                   | 10 (31.3)                   | 3 (9.38)                    | 17 (17.9)               |
| • A table and chair                                       | 16 (51.6)                  | 23 (71.9)                   | 16 (50)                     | 55 (57.9)               |
| • A refrigerator                                          | 2 (6.45)                   | 4 (12.5)                    | 2 (6.25)                    | 8 (8.42)                |
| • A watch                                                 | 5 (16.1)                   | 10 (31.3)                   | 4 (12.5)                    | 19 (20)                 |
| The family owns agricultural land                         |                            |                             |                             |                         |

## Supplementary Tables

| Variable N (%)                                                          | Standard<br>(N=31) | Elemental<br>(N=32) | Polymeric<br>(N=32) | Total<br>(N=95) |
|-------------------------------------------------------------------------|--------------------|---------------------|---------------------|-----------------|
|                                                                         | 21 (67.7)          | 25 (78.1)           | 19 (59.4)           | 65 (68.4)       |
| The principal households source of drinking water is (N; %):            |                    |                     |                     |                 |
| • Pipe inside dwelling                                                  | 1 (3.23)           | 0 (0.0)             | 0 (0.0)             | 1 (1.05)        |
| • Pipe outside dwelling/ to yard                                        | 1 (3.23)           | 3 (9.38)            | 1 (3.13)            | 5 (5.26)        |
| • Protected borehole/ well                                              | 9 (29)             | 15 (46.9)           | 9 (28.1)            | 33 (34.7)       |
| • Public tap                                                            | 16 (51.6)          | 11 (34.4)           | 18 (56.3)           | 45 (47.4)       |
| • Traditional public well                                               | 4 (12.9)           | 3 (9.38)            | 4 (12.5)            | 11 (11.6)       |
| • River/ canal/ lake                                                    | 0 (0.0)            | 0 (0.0)             | 0 (0.0)             | 0 (0.0)         |
| • Tanker truck                                                          | 0 (0.0)            | 0 (0.0)             | 0 (0.0)             | 0 (0.0)         |
| • Bottled water                                                         | 0 (0.0)            | 0 (0.0)             | 0 (0.0)             | 0 (0.0)         |
| • Rain water                                                            | 0 (0.0)            | 0 (0.0)             | 0 (0.0)             | 0 (0.0)         |
| • Cart with small tank                                                  | 0 (0.0)            | 0 (0.0)             | 0 (0.0)             | 0 (0.0)         |
| The principal type of toilet facility used by the household members is: |                    |                     |                     |                 |
| • Own (exclusive) flush                                                 | 0 (0.0)            | 0 (0.0)             | 0 (0.0)             | 0 (0.0)         |
| • Shared flush toilet                                                   | 0 (0.0)            | 0 (0.0)             | 0 (0.0)             | 0 (0.0)         |
| • Ventilated latrine                                                    | 6 (19.4)           | 8 (25)              | 6 (18.8)            | 20 (21.1)       |
| • Pit latrine with slab                                                 | 9 (29)             | 13 (40.6)           | 11 (34.4)           | 33 (34.7)       |
| • Pit latrine without slab/ open pit                                    | 16 (51.6)          | 11 (34.4)           | 15 (46.9)           | 42 (44.2)       |
| • Bush or field                                                         | 0 (0.0)            | 0 (0.0)             | 0 (0.0)             | 0 (0.0)         |
| The number of households using this toilet facility (mean; SD)          | 2.55 (1.43)        | 2.56 (2.06)         | 2.75(2.49)          | 2.62 (2.03)     |
| The principal type of flooring of the house:                            |                    |                     |                     |                 |
| • Tiles/cement/vinyl                                                    | 18 (58.1)          | 20 (62.5)           | 21 (65.6)           | 59 (62.1)       |
| • Wood/planks/broken bricks                                             | 1 (3.23)           | 0 (0.0)             | 0 (0.0)             | 1 (1.05)        |
| • Dirt/sand/dung                                                        | 12 (38.7)          | 12 (37.5)           | 11 (34.4)           | 35 (36.8)       |
| The principal type of roofing of the house:                             |                    |                     |                     |                 |

## Supplementary Tables

| Variable N (%)                                                                                       | Standard<br>(N=31) | Elemental<br>(N=32) | Polymeric<br>(N=32) | Total<br>(N=95) |
|------------------------------------------------------------------------------------------------------|--------------------|---------------------|---------------------|-----------------|
| • Cement                                                                                             | 0 (0.0)            | 0 (0.0)             | 0 (0.0)             | 0 (0.0)         |
| • Wood planks/cardboard                                                                              | 0 (0.0)            | 0 (0.0)             | 0 (0.0)             | 0 (0.0)         |
| • Iron and tiles                                                                                     | 2 (6.45)           | 0 (0.0)             | 1 (3.13)            | 3 (3.16)        |
| • Iron sheets                                                                                        | 23 (74.2)          | 21 (65.6)           | 23 (71.9)           | 67 (70.5)       |
| • Natural materials                                                                                  | 6 (19.4)           | 11 (34.4)           | 8 (25)              | 25 (26.3)       |
| A member of the household owns a bank account:                                                       | 8 (25.8)           | 8 (25)              | 7 (21.9)            | 23 (24.2)       |
| The usual daily income for the family is:<br>(1 Malawian kwacha (MWK) = 0.0014 United States Dollar) |                    |                     |                     |                 |
| • <500 MWK                                                                                           | 3 (9.68)           | 2 (6.25)            | 1 (3.13)            | 6 (6.32)        |
| • 500 - 1000 MWK                                                                                     | 23 (74.2)          | 19 (59.4)           | 23 (71.9)           | 65 (68.4)       |
| • >1000 MWK                                                                                          | 5 (16.1)           | 11 (34.4)           | 8 (25)              | 24 (25.3)       |
| In the past 12 months, the inside walls of the house have been treated against mosquitoes            | 2 (6.45)           | 3 (9.38)            | 1 (3.13)            | 6 (6.32)        |
| The number of mosquito nets used for sleeping in the household (mean; SD)                            | 2(1.24)            | 2.41(1.88)          | 2.13(1.84)          | 2.18(1.68)      |
| Type of fuel mainly used for cooking:                                                                |                    |                     |                     |                 |
| • Electricity                                                                                        | 0 (0.0)            | 1 (3.13)            | 0 (0.0)             | 1 (1.05)        |
| • Charcoal                                                                                           | 22 (71)            | 15 (46.9)           | 20 (62.5)           | 57 (60)         |
| • Wood                                                                                               | 9 (29)             | 16 (50)             | 12 (37.5)           | 37 (38.9)       |
| • Natural gas                                                                                        | 0 (0.0)            | 0 (0.0)             | 0 (0.0)             | 0 (0.0)         |
| • Biogas                                                                                             | 0 (0.0)            | 0 (0.0)             | 0 (0.0)             | 0 (0.0)         |
| • Kerosene                                                                                           | 0 (0.0)            | 0 (0.0)             | 0 (0.0)             | 0 (0.0)         |
| • Straw/shrubs/grass                                                                                 | 0 (0.0)            | 0 (0.0)             | 0 (0.0)             | 0 (0.0)         |
| Type of stove/fire used for cooking:                                                                 |                    |                     |                     |                 |
| • Open fire                                                                                          | 29 (93.5)          | 31 (96.9)           | 30 (93.8)           | 90 (94.7)       |
| • Stove without chimney/ flute                                                                       | 2 (6.45)           | 1 (3.13)            | 2 (6.25)            | 5 (5.26)        |
| • Stove with chimney/ flute                                                                          | 0 (0.0)            | 0 (0.0)             | 0 (0.0)             | 0 (0.0)         |

# Supplementary Tables

| <b>Variable N (%)</b>                                  | <b>Standard<br/>(N=31)</b> | <b>Elemental<br/>(N=32)</b> | <b>Polymeric<br/>(N=32)</b> | <b>Total<br/>(N=95)</b> |
|--------------------------------------------------------|----------------------------|-----------------------------|-----------------------------|-------------------------|
| Location where cooking is usually done:                |                            |                             |                             |                         |
| • In the house                                         | 8 (25.8)                   | 7 (21.9)                    | 12 (37.5)                   | 27 (28.4)               |
| • In a separate building                               | 4 (12.9)                   | 7 (21.9)                    | 4 (12.5)                    | 15 (15.8)               |
| • Outside                                              | 19 (61.3)                  | 18 (56.3)                   | 16 (50)                     | 53 (55.8)               |
| The highest education level of the main care giver is: |                            |                             |                             |                         |
| • No education                                         | 3 (9.68)                   | 2 (6.25)                    | 1 (3.13)                    | 6 (6.32)                |
| • some primary education                               | 17 (54.8)                  | 12 (37.5)                   | 21 (65.6)                   | 50 (52.6)               |
| • Completed primary education                          | 3 (9.68)                   | 5 (15.6)                    | 2 (6.25)                    | 10 (10.5)               |
| • some secondary education                             | 6 (19.4)                   | 11 (34.4)                   | 5 (15.6)                    | 22 (23.2)               |
| • Completed secondary education                        | 2 (6.45)                   | 2 (6.25)                    | 3 (9.38)                    | 7 (7.37)                |
| • More than secondary education                        | 0 (0.0)                    | 0 (0.0)                     | 0 (0.0)                     | 0 (0.0)                 |

Supplementary Table S3 – **Baseline characteristics according to presence of oedema**

| <b>Variable (N, mean, <math>\pm</math> SD)</b>       | <b>Without Oedema (N=57)</b> | <b>With Oedema (N=38)</b> | <b>P-value</b> |
|------------------------------------------------------|------------------------------|---------------------------|----------------|
| <b>Demographic</b>                                   |                              |                           |                |
| Male (%)                                             | 26/57 (46.7 %)               | 20/38 (52.7 %)            | 0.50           |
| Age in months                                        | 57, 12.8 $\pm$ 4.8           | 38, 17.9 $\pm$ 5.4        | <0.001         |
| <b>Anthropometry</b>                                 |                              |                           |                |
| Mid-Upper-Arm-Circumference (cm)                     | 57, 10.6 $\pm$ 1.2           | 38, 14.3 $\pm$ 14.2       | <0.001         |
| <b>Laboratory</b>                                    |                              |                           |                |
| Faecal calprotectin ( $\mu$ g/mg)                    | 48, 660.8 $\pm$ 1040.7       | 30, 496.8 $\pm$ 545.2     | 0.885          |
| Faecal $\alpha_1$ -antitrypsin (mg/dL)               | 49, 8.4 $\pm$ 24.6           | 29, 4.7 $\pm$ 5.9         | 0.842          |
| Plasma IgG anti-endotoxin antibodies (GMU/ml)        | 34, 94.3 $\pm$ 101.9         | 27, 96 $\pm$ 144.7        | 0.689          |
| Plasma intestinal fatty acid binding protein (pg/ml) | 34, 4310.6 $\pm$ 2652.2      | 26, 4862.8 $\pm$ 3150.9   | 0.464          |
| Platelets ( $\times 10^9$ /L)                        | 33, 445.8 $\pm$ 290.8        | 26, 475.3 $\pm$ 234.8     | 0.676          |
| Plasma C-reactive protein (mg/L)                     | 33, 28.2 $\pm$ 50            | 27, 18 $\pm$ 21.8         | 0.768          |
| Plasma $\alpha_1$ -acid glycoprotein ( $\mu$ g/ml)   | 34, 2864.4 $\pm$ 993.3       | 27, 3403.9 $\pm$ 780.2    | 0.024          |
| Insulin-like growth factor-1 (ng/ml)                 | 22, 51.9 $\pm$ 27.5          | 15, 46.7 $\pm$ 27.4       | 0.687          |
| Insulin-like growth factor binding protein 3 (ng/ml) | 34, 785.3 $\pm$ 354.5        | 26, 888.2 $\pm$ 349       | 0.267          |
| Haemoglobin (g/dL)                                   | 33, 9.6 $\pm$ 1.1            | 26, 9.2 $\pm$ 1.4         | 0.198          |
| White cell count ( $\times 10^9$ /L)                 | 33, 12.5 $\pm$ 5             | 26, 12.3 $\pm$ 5.2        | 0.906          |

Data was analysed using a one-way ANOVA, and variables which were not normally distributed were logarithmically transformed to detect any overall differences in group means according to oedema status

Supplementary Table S4 – **Baseline characteristics according to HIV status**

| Variable (N, mean, $\pm$ SD)                         | HIV Negative (N=60)    | HIV Positive (N=34)     | P-value |
|------------------------------------------------------|------------------------|-------------------------|---------|
| <b>Demographic</b>                                   |                        |                         |         |
| Male (%)                                             | 28 (29.8 %)            | 18 (19.1 %)             | 0.56    |
| Age in months                                        | 60, 14.9 $\pm$ 5.8     | 34, 14.9 $\pm$ 5.3      | 0.805   |
| <b>Clinical</b>                                      |                        |                         |         |
| Mid-Upper-Arm-Circumference (cm),                    | 59, 11.5 $\pm$ 1.3     | 34, 10.6 $\pm$ 1.4      | 0.002   |
| Weight-for-length Z-score <sup>1</sup>               | 32, -3.5 $\pm$ 1.2     | 24, -3.9 $\pm$ 1.2      | 0.254   |
| With Oedema (%)                                      | 28 (29.8 %)            | 10 (10.6 %)             | 0.10    |
| <b>Laboratory</b>                                    |                        |                         |         |
| Faecal calprotectin ( $\mu$ g/mg stool)              | 49, 423.5 $\pm$ 712.6  | 29, 892.1 $\pm$ 1063    | 0.005   |
| Faecal $\alpha_1$ -antitrypsin (mg/dL)               | 50, 4.6 $\pm$ 5.2      | 28, 11.3 $\pm$ 32.3     | 0.368   |
| Plasma IgG anti-endotoxin antibodies (GMU/ml)        | 41, 84.5 $\pm$ 112.9   | 20, 116.8 $\pm$ 138.3   | 0.090   |
| Plasma Intestinal fatty acid binding protein (pg/ml) | 40, 4760 $\pm$ 2991.7  | 20, 4129.7 $\pm$ 2620.5 | 0.427   |
| Platelets ( $\times 10^9$ /L)                        | 39, 493.9 $\pm$ 259.8  | 20, 390.3 $\pm$ 270.5   | 0.158   |
| Plasma C-reactive protein (mg/L)                     | 40, 16.2 $\pm$ 23.6    | 20, 38.4 $\pm$ 58.9     | 0.008   |
| Plasma $\alpha_1$ -acid glycoprotein ( $\mu$ g/ml)   | 41, 2945.4 $\pm$ 941.2 | 20, 3426.7 $\pm$ 865    | 0.059   |
| Insulin-like growth factor -1 (ng/ml)                | 29, 49.2 $\pm$ 25.5    | 8, 51.7 $\pm$ 34.4      | 0.854   |
| Insulin-like growth factor binding protein 3 (ng/ml) | 40, 896.5 $\pm$ 381.9  | 20, 696.7 $\pm$ 243.7   | 0.038   |
| Haemoglobin (g/dL)                                   | 39, 9.8 $\pm$ 1.1      | 20, 8.9 $\pm$ 1.3       | 0.007   |
| White cell count ( $\times 10^9$ /L)                 | 39, 13 $\pm$ 4.7       | 20, 11.3 $\pm$ 5.4      | 0.207   |

Data was analysed using a one-way ANOVA, and variables which were not normally distributed were logarithmically transformed to detect any overall differences in group means according to HIV status.

<sup>1</sup>In children without oedema

Supplementary Table S5– **Biomarkers of systemic and intestinal inflammation and mucosal integrity**

|                                                                                 |     | All children            |                      | Intervention arms          |                             |                             | Intervention vs. standard                         |                                                  |
|---------------------------------------------------------------------------------|-----|-------------------------|----------------------|----------------------------|-----------------------------|-----------------------------|---------------------------------------------------|--------------------------------------------------|
| Variable                                                                        | Day | Total<br>n<br>mean (SD) | P value <sup>1</sup> | Standard<br>n<br>mean (SD) | Elemental<br>n<br>mean (SD) | Polymeric<br>n<br>mean (SD) | Elemental vs.<br>Standard<br>P value <sup>2</sup> | Polymeric<br>vs Standard<br>P value <sup>2</sup> |
| Intestinal inflammation                                                         |     |                         |                      |                            |                             |                             |                                                   |                                                  |
| Faecal calprotectin<br>(µg/mg; normal <50)                                      | 0   | 71<br>547 (744)         | 0.31                 | 23<br>555 (732)            | 25<br>646 (797)             | 23<br>433 (711)             | 0.68                                              | 0.57                                             |
|                                                                                 | 14  | 67<br>697 (735)         |                      | 23<br>538 (643)            | 19<br>803 (788)             | 25<br>763 (777)             | 0.24                                              | 0.28                                             |
| Mucosal integrity                                                               |     |                         |                      |                            |                             |                             |                                                   |                                                  |
| Faecal α <sub>1</sub> -antitrypsin<br>(mg/dl; normal <26.8)                     | 0   | 64<br>25.4 (31.1)       | 0.0046               | 23<br>26.9 (38)            | 21<br>18.4 (12.7)           | 20<br>31 (35.8)             | 0.32                                              | 0.72                                             |
|                                                                                 | 14  | 58<br>46.9 (44.2)       |                      | 19<br>30.8 (33.6)          | 19<br>45.3 (37.2)           | 20<br>63.8 (54.1)           | 0.22                                              | 0.028                                            |
| Plasma IgG anti-<br>endotoxin antibodies<br>(GMU/ml; normal: none<br>detected)  | 0   | 46<br>95.6 (128.5)      | 0.71                 | 15<br>73.4 (53.6)          | 16<br>151.6 (199.4)         | 15<br>57.9 (45)             | 0.15                                              | 0.4                                              |
|                                                                                 | 14  | 45<br>87.2 (131.7)      |                      | 17<br>112.7 (202.6)        | 12<br>63.1(40.4)            | 16<br>78.2 (68.1)           | 0.34                                              | 0.51                                             |
| Plasma Intestinal fatty<br>acid binding protein<br>(pg/ml; normal 389-<br>2129) | 0   | 44<br>4474 (2845)       | 0.64                 | 15<br>3488 (1970)          | 14<br>4664 (2453)           | 15<br>5284 (3688)           | 0.16                                              | 0.11                                             |
|                                                                                 | 14  | 45<br>4220 (2316)       |                      | 16<br>4748 (2735)          | 13<br>4235 (2256)           | 16<br>3682 (1890)           | 0.59                                              | 0.21                                             |
| Systemic inflammation                                                           |     |                         |                      |                            |                             |                             |                                                   |                                                  |
| Platelets (x10 <sup>9</sup> /L blood;                                           | 0   | 46                      |                      | 17                         | 13                          | 16                          | 0.98                                              | 0.76                                             |

|                                                                       |    |                    |         |                   |                     |                     |       |        |
|-----------------------------------------------------------------------|----|--------------------|---------|-------------------|---------------------|---------------------|-------|--------|
| normal 150-450)                                                       |    | 473.9(272.2)       | 0.003   | 463.8 (302.2)     | 466.2 (337.5)       | 490.9 (182.6)       |       |        |
|                                                                       | 14 | 46<br>593.8(296.5) |         | 16<br>599.4 (266) | 14<br>646.0 (300.6) | 16<br>542.4 (330.5) | 0.66) | 0.59   |
| Plasma C-reactive protein (mg/L; normal 0.104 – 4.19)                 | 0  | 44<br>26.4 (44.6)  | 0.07    | 14<br>19.7 (17.8) | 15<br>21.7 (25.3)   | 15<br>37.3 (70.5)   | 0.81  | 0.36   |
|                                                                       | 14 | 45<br>12.2 (28.1)  |         | 16<br>13.1 (29.8) | 13<br>6.8 (12.7)    | 16<br>15.7(35.6)    | 0.46  | 0.82   |
| Plasma α <sub>1</sub> -acid glycoprotein (µg/ml; normal 322-1143)     | 0  | 45<br>3256 (909)   | <0.0001 | 14<br>3315 (855)  | 16<br>3292 (950)    | 15<br>3164 (966)    | 0.94  | 0.66   |
|                                                                       | 14 | 43<br>1969 (1001)  |         | 15<br>2530 (1036) | 12<br>2086 (945)    | 16<br>1356 (650)    | 0.26  | 0.0007 |
| Growth factors                                                        |    |                    |         |                   |                     |                     |       |        |
| Insulin-like growth factor-1 (ng/ml; normal 40-258)                   | 0  | 27<br>48 (27)      | <0.0001 | 8<br>43.8 (24.1)  | 7<br>62.1 (30.4)    | 12<br>42.5 (25.9)   | 0.22  | 0.91   |
|                                                                       | 14 | 29<br>112.7 (67.4) |         | 9<br>77.1 (57)    | 7<br>162.8 (83.1)   | 13<br>110.3 (50.7)  | 0.028 | 0.17   |
| Insulin-like growth factor binding protein 3 (ng/ml; normal 853-3778) | 0  | 44<br>827 (337)    | <0.0001 | 15<br>826 (345)   | 14<br>830.8(263)    | 15<br>825 (408)     | 0.97  | 1.0    |
|                                                                       | 14 | 45<br>1434 (586)   |         | 16<br>1328 (657)  | 13<br>1427 (3589)   | 16<br>1545 (669)    | 0.61  | 0.36   |
| Anthropometry                                                         |    |                    |         |                   |                     |                     |       |        |
| Mid-upper arm circumference                                           | 0  | 93<br>11.2 (1.3)   | <0.0001 | 30<br>10.9 (1.4)  | 31<br>11.2 (1.6)    | 32<br>11.4 (0.9)    | 0.39  | 0.07   |
|                                                                       | 14 | 93<br>11.8 (1.5)   |         | 30<br>11.4 (1.4)  | 31<br>11.9 (1.7)    | 32<br>12.2 (1.1)    | 0.19  | 0.01   |
| Weight                                                                | 0  | 91                 |         | 30                | 30                  | 31                  | 0.41  | 0.83   |

|                           |    |                  |         |                  |                  |                  |      |      |
|---------------------------|----|------------------|---------|------------------|------------------|------------------|------|------|
|                           |    | 6.3 (1.5)        | <0.0001 | 6.5 (1.7)        | 6.1 (1.8)        | 6.4 (1.1)        |      |      |
|                           | 14 | 91<br>6.9 (1.6)  |         | 30<br>7.0 (1.7)  | 30<br>6.7 (1.8)  | 31<br>7.0 (1.3)  | 0.61 | 0.78 |
| Weight-for-length Z-score | 0  | 91<br>-3.2 (1.4) | <0.0001 | 30<br>-3.4 (1.5) | 30<br>-3.0 (1.6) | 31<br>-3.2 (1.2) | 0.30 | 0.47 |
|                           | 14 | 91<br>-2.3 (1.5) |         | 30<br>-2.6 (1.5) | 30<br>-2.1 (1.8) | 31<br>-2.2 (1.2) | 0.19 | 0.27 |

1. Data was analysed using a paired t-test to detect any overall difference between day 0 (up to day 3) and day 14 ( $\pm$  3 days), and was logarithmically transformed for variables which were not normally distributed. Where the data was still not normal after this transformation a Wilcoxon signed-rank test was performed as an alternative.
2. Independent t-test comparing each intervention treatment group to the standard

## Supplementary Tables

Supplementary Table S6 – **Feeding and clinical symptoms according to intervention arm**

| Variable <sup>1</sup>                         | Standard<br>(N=31) | Elemental<br>(N=32) | Polymeric<br>(N=32) | Elemental<br>vs.<br>standard<br>P value <sup>2</sup> | Polymeric<br>vs.<br>standard<br>P value <sup>2</sup> |
|-----------------------------------------------|--------------------|---------------------|---------------------|------------------------------------------------------|------------------------------------------------------|
| <b>Feeding</b>                                |                    |                     |                     |                                                      |                                                      |
| • Required nasogastric tube feeds             | 6 (19.4)           | 15 (46.9)           | 11 (34.4)           | 0.021                                                | 0.18                                                 |
| • Required F75                                | 8 (25.8)           | 6 (18.8)            | 0 (0)               | 0.50                                                 | 0.002                                                |
| No. days completed feed: mean (SD)            | 12.0 (4.1)         | 11.0 (4.3)          | 12.1 (3.5)          | 0.32                                                 | 0.98                                                 |
| <b>Symptoms and signs</b>                     |                    |                     |                     |                                                      |                                                      |
| Stool frequency/day                           | 3.6 (1.93)         | 3.9 (2.0)           | 3.4 (1.9)           | 0.047                                                | 0.13                                                 |
| Children who experienced between day 0 and 14 |                    |                     |                     |                                                      |                                                      |
| • Vomiting                                    | 10 (32.3)          | 19 (59.4)           | 19 (59.4)           | 0.031                                                | 0.031                                                |
| • Loose stools                                | 22 (71)            | 26 (81.3)           | 26 (81.3)           | 0.34                                                 | 0.34                                                 |
| • Watery stools                               | 5 (16.1)           | 9 (28.1)            | 7 (21.9)            | 0.25                                                 | 0.56                                                 |
| • Mucus in stools                             | 0 (0)              | 2 (6.3)             | 0 (0)               | 0.49                                                 | -                                                    |
| • Blood in stools                             | 1 (3.23)           | 0 (0)               | 2 (6.25)            | 0.49                                                 | 1.0                                                  |
| On day 14, children with                      |                    |                     |                     |                                                      |                                                      |
| • Loose/watery stools                         | 6 (26.1)           | 5 (19.2)            | 6 (18.8)            | 0.97                                                 | 1.0                                                  |
| • Any oedema                                  | 2 (6.5)            | 3 (9.4)             | 1 (3.1)             | -                                                    | -                                                    |

<sup>1</sup>Data are n (%) unless shown otherwise. <sup>2</sup>Data was analysed using a Chi-Square test for n (%) data, a t-test for stool frequency/day and Generalized Linear Analysis for number of days completed feed with Poisson distribution and a link log.

## Supplementary Tables

**Supplementary Table S7 – Severe adverse events according to MedDRA preferred term, intervention group and outcome**

|                                       | <b>Total</b> | <b>Standard</b>       | <b>Elemental</b>      | <b>Polymeric</b> |
|---------------------------------------|--------------|-----------------------|-----------------------|------------------|
|                                       |              | <b>N=31</b>           | <b>N=32</b>           | <b>N=32</b>      |
| <b>Number (%) of children</b>         | <b>25</b>    | 9 <sup>2</sup> (29.0) | 9 <sup>2</sup> (28.1) | 7 (21.9)         |
| MedDRA preferred term                 |              |                       |                       |                  |
| · Gastroenteritis                     | 13           | 4                     | 8                     | 1                |
| · Dehydration                         | 11           | 5                     | 5                     | 1                |
| · Sepsis                              | 6            | -                     | 3                     | 3                |
| · Metabolic acidosis                  | 3            | -                     | 2                     | 1                |
| · Pulmonary tuberculosis <sup>1</sup> | 3            | 1                     | -                     | 2                |
| · Pneumonia                           | 1            | 1                     | -                     | -                |
| · Septic shock                        | 1            | -                     | 1                     | -                |
| · Hypoglycaemia                       | 1            | -                     | -                     | 1                |
| · Urticaria drug-induced              | 1            | 1                     | -                     | -                |
| · Hypovolemic shock                   | 1            | 1                     | -                     | -                |
| · Acute kidney injury                 | 1            | -                     | 1                     | -                |
| · Unknown <sup>3</sup>                | 1            | -                     | -                     | 1                |
| Total number SAEs                     | 43           | 13                    | 20                    | 10               |
| Total number deaths                   | 7            | 2                     | 2                     | 3                |

A total of 43 SAEs occurred in 25 children. <sup>1</sup>Treatment for tuberculosis was on-going in these 3 cases at the end of the study. <sup>2</sup>Two patients (one in the control group and one in the elemental group) had an SAE onset within the study period but died one day after the 14th day. <sup>3</sup>20-month-old boy, HIV positive, malaria slide negative, admitted with oedematous SAM, gastroenteritis, oral thrush and septicaemia. He was reported to be well on review on the third study day but then died suddenly and the cause was unclear. The results of an initial blood culture were not available.